<DOC>
	<DOCNO>NCT02607982</DOCNO>
	<brief_summary>This study aim assess efficiency safety concurrent chemoradiotherapy ( CCRT ) use paclitaxel ( PTX ) plus oxaliplatin ( OHP ) unresectable locally advanced esophageal cancer patient .</brief_summary>
	<brief_title>CCRT Esophageal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Cytologically histologically confirm esophageal carcinoma 2 . Age 20 80 3 . ECOG performance status : 01 ; 4 . No treatment prior enrollment ; 5 . At least one measurable lesion CT , MRI esophageal barium exam ; 6 . Normal function heart , lung , liver , kidney bone marrow 7 . Blood exam qualify chemotherapy , include hemoglobulin ≥9 g/dl , neutrophil ≥1.5×109/L platelet ( PLT ) ≥100×109/L , creatinine ≤1.5 UNL 8 . Informed consent sign 1 . Prior treatment chemotherapy irradiation ; 2 . Poor bone marrow , liver kidney function , would make chemotherapy intolerable ; 3 . Contraindication irradiation : complete obstruction esophagus , deep esophageal ulcer , fistula mediastinum , haematemesis ; 4 . Participating clinical trial ; 5 . Pregnancy , breast feeding , adopt birth control ; 6 . Clinically significant uncontrolled major medical condition include limited : active uncontrolled infection , symptomatic congestive heart failure , Unstable angina pectoris cardiac arrhythmia , psychiatric illness/ social situation would limit compliance study requirement ; medical condition , opinion study investigator place subject unacceptably high risk toxicity 7 . The subject another active malignancy within past five year except cervical cancer site , situ carcinoma bladder nonmelanoma carcinoma skin ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Survival</keyword>
	<keyword>Toxicity</keyword>
</DOC>